TABLE 2.
Demographic and clinical characteristics of participants stratified by APOE ε4 carrier status.
| APOE ε4 non-carriers N = 159 | With one APOE ε4 allele N = 114 | The APOE ε4/ε4 genotype N = 36 | P | |
| Age, years | 75.76 ± 6.90 | 75.33 ± 6.45 | 71.61 ± 6.85 | 0.0040 |
| Men | 95 (59.75) | 72 (63.16) | 20 (55.56) | 0.6897 |
| BMI, kg/m2 | 26.31 ± 4.50 | 25.07 ± 3.42 | 25.69 ± 3.82 | 0.1102 |
| Educational level, years | 15.90 ± 3.01 | 15.61 ± 3.07 | 15.00 ± 2.20 | 0.1203 |
| CSF ApoE | 7.46 ± 2.29 | 6.76 ± 2.23 | 6.40 ± 2.08 | <0.0001 |
| CSF Aβ | 199.00 ± 53.84 | 146.70 ± 34.26 | 117.90 ± 22.52 | <0.0001 |
| CSF t-tau | 82.96 ± 48.17 | 112.50 ± 51.85 | 120.62 ± 50.64 | <0.0001 |
| CSF p-tau | 28.24 ± 15.57 | 38.92 ± 15.98 | 42.74 ± 20.49 | <0.0001 |
| Cardiovascular disease | 54 (33.96) | 36 (31.58) | 9 (25.00) | 0.5768 |
| Hypertension | 85 (53.46) | 49 (42.98) | 16 (44.44) | 0.2027 |
| Hyperlipoidemia | 62 (38.99) | 57 (50.00) | 23 (63.89) | 0.0142 |
| Depression | 29 (18.24) | 24 (21.05) | 7 (19.45) | 0.8454 |
| Mean follow-up, years | 2.31 ± 1.53 | 2.01 ± 1.34 | 1.81 ± 1.37 | 0.0624 |
BMI, body mass index; CSF, cerebrospinal fluid; ApoE, Apolipoprotein E; Aβ, amyloid-β; p-tau, phosphorylated tau; t-tau, total tau; MCI, mild cognitive impairment; CN, cognitively normal; AD, Alzheimer’s disease. Categorical data are shown as n (%) and continuous data are shown as mean ± SD.